share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax製藥 | 8-K:重大事件
美股SEC公告 ·  10/05 04:35

牛牛AI助理已提取核心訊息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VRPX, has received a delisting notice from Nasdaq. The notice, dated October 3, 2024, was issued after the company failed to meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b). Despite submitting a compliance plan and being granted an extension until September 30, 2024, Virpax Pharmaceuticals was unable to regain compliance within the allotted timeframe. The company has been informed that unless it appeals, trading of its common stock will be suspended starting October 14, 2024, followed by the filing of a Form 25-NSE to formally delist the stock. Virpax Pharmaceuticals plans to request a hearing with the Nasdaq Hearings Panel, which could delay the delisting process until the conclusion of the hearing and any further extensions granted. However, there is no guarantee that the Panel will grant an additional extension or that the company will be able to meet the continued listing requirements in the future.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VRPX, has received a delisting notice from Nasdaq. The notice, dated October 3, 2024, was issued after the company failed to meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b). Despite submitting a compliance plan and being granted an extension until September 30, 2024, Virpax Pharmaceuticals was unable to regain compliance within the allotted timeframe. The company has been informed that unless it appeals, trading of its common stock will be suspended starting October 14, 2024, followed by the filing of a Form 25-NSE to formally delist the stock. Virpax Pharmaceuticals plans to request a hearing with the Nasdaq Hearings Panel, which could delay the delisting process until the conclusion of the hearing and any further extensions granted. However, there is no guarantee that the Panel will grant an additional extension or that the company will be able to meet the continued listing requirements in the future.
Virpax Pharmaceuticals, Inc.是一家註冊地爲特拉華州的公司,在納斯達克資本市場以交易代碼VRPX進行交易。該公司收到了納斯達克的退市通知。該通知日期爲2024年10月3日,是因爲公司未能達到納斯達克第5550(b)條上市規則規定的250萬美元最低股東權益要求而發出的。儘管提交了符合計劃並獲得了延期至2024年9月30日的延期,但Virpax Pharmaceuticals未能在規定時間內恢復合規。公司已被告知,除非上訴,其普通股的交易將於2024年10月14日起暫停,隨後將提交一份Form 25-NSE正式將股票除牌。Virpax Pharmaceuticals計劃要求與納斯達克聽證會議小組進行聽證,這可能會延遲退市流程直至聽證會議和任何進一步的延期結束。然而,並不能保證小組會批准額外的延期或該公司將能夠在未來達到持續上市的要求。
Virpax Pharmaceuticals, Inc.是一家註冊地爲特拉華州的公司,在納斯達克資本市場以交易代碼VRPX進行交易。該公司收到了納斯達克的退市通知。該通知日期爲2024年10月3日,是因爲公司未能達到納斯達克第5550(b)條上市規則規定的250萬美元最低股東權益要求而發出的。儘管提交了符合計劃並獲得了延期至2024年9月30日的延期,但Virpax Pharmaceuticals未能在規定時間內恢復合規。公司已被告知,除非上訴,其普通股的交易將於2024年10月14日起暫停,隨後將提交一份Form 25-NSE正式將股票除牌。Virpax Pharmaceuticals計劃要求與納斯達克聽證會議小組進行聽證,這可能會延遲退市流程直至聽證會議和任何進一步的延期結束。然而,並不能保證小組會批准額外的延期或該公司將能夠在未來達到持續上市的要求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。